These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21458847)

  • 1. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin.
    Jeske WP; Hoppensteadt D; Gray A; Walenga JM; Cunanan J; Myers L; Fareed J; Bayol A; Rigal H; Viskov C
    Thromb Res; 2011 Oct; 128(4):361-7. PubMed ID: 21458847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical studies on sulfated lactobionic acid amides.
    Klauser RJ; Meinetsberger E; Raake W
    Semin Thromb Hemost; 1991; 17 Suppl 1():118-25. PubMed ID: 1648790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
    Ammollo CT; Semeraro F; Semeraro N; Colucci M
    Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
    [No Abstract]   [Full Text] [Related]  

  • 7. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facts and artefacts of coagulation assays for factor Xa inhibitors.
    Haas S
    Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
    [No Abstract]   [Full Text] [Related]  

  • 11. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
    Martínez-González J; Vila L; Rodríguez C
    Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):793-802. PubMed ID: 18570617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
    Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
    Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin.
    Stief TW
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):633-7. PubMed ID: 17102649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a heparin-binding protein on blood coagulation and platelet function.
    Kaiser P; Harenberg J; Walenga JM; Huhle G; Giese C; Prechel M; Hoppensteadt D; Fareed J
    Semin Thromb Hemost; 2001 Oct; 27(5):495-502. PubMed ID: 11668419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.